【ChiCTR2300072972】Association between laboratory parameters analysis and clinical severity in patients with coronavirus disease (Covid 19) at Hospital Universitario Fundación Santa Fe
ChiCTR2300072972
结束
/
/
/
2023-06-29
/
/
Covid 19
Association between laboratory parameters analysis and clinical severity in patients with coronavirus disease (Covid 19) at Hospital Universitario Fundación Santa Fe
Association between laboratory parameters analysis and clinical severity in patients with coronavirus disease (Covid 19) at Hospital Universitario Fundación Santa Fe
This study aims to determine the association between laboratory parameters of COVID-19 patients and clinical disease severity to provide applicable information to improved treatment strategies.
队列研究
回顾性研究
N/A
N/A
Self-funded
/
296
/
2020-01-01
2022-01-23
/
1. The study population comprised patients with confirmed or suspected SARS-CoV-2 infection according to the Colombian consensus of attention, diagnostic, and treatment of COVID-19 infection, an expert consensus; 2. Patients were tested for SARS-CoV-2, and the diagnosis was made using the real-time reverse transcriptase-polymerase chain reaction (rt-PCR) test or antigens for SARS-CoV-2 test; 3. All hospitalized patients with more than 5 days and with a positive RT-PCR assay or antigens test for SARS-CoV-2 were included in the study; 4. Positive COVID-19 diagnosis patients lists were recollected on a database used by the Hospital Universitario Fundación Santa Fe de Bogotá; 5. Decisions about the necessity of hospitalization were made by emergency physicians in accordance with the same guidelines, and the use of severity-based classification variables, patient clinical state, and paraclinical information, independent of inpatient bed availability; 6. Patients were only included if requiring hospitalization was available at the emergency department, or hospitalization bed, or intensive care unit bed became available.;
请登录查看1. Transferred patients were not included; 2. Those patients who did not undergo molecular tests or tested negative were excluded from the study; 3.Patients who have the infection for the second time.;
请登录查看MD pathologist; Fundación Santa Fé de Bogotá
/
MD pathologist; Fundación Santa Fé de Bogotá的其他临床试验
MD pathologist; Fundación Santa Fé de Bogotá的其他临床试验
最新临床资讯
-
大鹏制药临床III期成功
新药说2026-08-13
-
新一代 EGFR-TKI 首个全球 III 期成功
丁香园 Insight 数据库2026-08-13
-
体外诊断原料网2026-08-13
-
佰傲谷BioValley2026-08-13
-
久有基金2026-08-13
-
重庆宸安生物2026-08-13
-
UmabsDB2026-08-13
-
希格生科2026-08-13
-
bioSeedin柏思荟2026-08-13
-
智飞智讯2026-08-13
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-08-14
-
2026-08-14
-
2026-08-14
-
摩熵咨询 20 8
-
摩熵咨询 34 28
-
摩熵咨询 20 5
-
颁布机构:四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构:国家医保局 2026-07-31
-
颁布机构:国家药品审评中心(CDE) 2026-07-24
同适应症药物临床试验
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-08-14
-
2026-08-13
-
2026-08-13
-
摩熵咨询 35 36
-
摩熵咨询 28 39
-
摩熵咨询 34 18
-
颁布机构:国家市场监督管理总局 2026-08-10
-
颁布机构:国家市场监督管理总局 2026-05-29
-
颁布机构:国家市场监督管理总局 2026-05-29
